Baton Rouge-based TransGenRx Inc. will pay $1.3 million to a London firm to develop and scale up a recombinant interferon product under a contract announced Tuesday.

The development work will be done at Angel Biotechnology Holdings PLC's facility in Cramlington, England.

"The development and production of this interferon product is key to the future of TransGenRx, hence the reason we have entrusted its delivery to the team at Angel," TransGenRx Executive Vice President Richard Cooper said in a news release. "We are confident this will be the first of a number of projects that we would like to progress with Angel."

TransGenRx, a biopharmaceutical company, was founded in 2002 through licensing agreements with the LSU AgCenter. The company is based in the Louisiana Emerging Technology Center on the LSU campus.